Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

Gunter von Minckwitz, Chiun-Sheng Huang, Max S. Mano, Sibylle Loibl, Eleftherios P. Mamounas, Michael Untch, Norman Wolmark, Priya Rastogi, Andreas Schneeweiss, Andres Redondo, Hans H. Fischer, William Jacot, Alison K. Conlin, Claudia Arce-Salinas, Irene L. Wapnir, Christian Jackisch, Michael P. DiGiovanna, Peter A. Fasching, John P. Crown, Pia Wülfing, Zhimin Shao, Elena Rota Caremoli, Haiyan Wu, Lisa H. Lam, David Tesarowski, Melanie Smitt, Hannah Douthwaite, Stina M. Singel, Charles E. Geyer

Open source

DOI: 10.1056/nejmoa1814017
Published: 2019-02-14
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa1814017,
  title = {Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer},
  author = {Gunter von Minckwitz and Chiun-Sheng Huang and Max S. Mano and Sibylle Loibl and Eleftherios P. Mamounas and Michael Untch and Norman Wolmark and Priya Rastogi and Andreas Schneeweiss and Andres Redondo and Hans H. Fischer and William Jacot and Alison K. Conlin and Claudia Arce-Salinas and Irene L. Wapnir and Christian Jackisch and Michael P. DiGiovanna and Peter A. Fasching and John P. Crown and Pia Wülfing and Zhimin Shao and Elena Rota Caremoli and Haiyan Wu and Lisa H. Lam and David Tesarowski and Melanie Smitt and Hannah Douthwaite and Stina M. Singel and Charles E. Geyer},
  year = {2019},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa1814017},
  url = {https://doi.org/10.1056/nejmoa1814017}
}

RIS

TY  - JOUR
TI  - Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
AU  - Gunter von Minckwitz
AU  - Chiun-Sheng Huang
AU  - Max S. Mano
AU  - Sibylle Loibl
AU  - Eleftherios P. Mamounas
AU  - Michael Untch
AU  - Norman Wolmark
AU  - Priya Rastogi
AU  - Andreas Schneeweiss
AU  - Andres Redondo
AU  - Hans H. Fischer
AU  - William Jacot
AU  - Alison K. Conlin
AU  - Claudia Arce-Salinas
AU  - Irene L. Wapnir
AU  - Christian Jackisch
AU  - Michael P. DiGiovanna
AU  - Peter A. Fasching
AU  - John P. Crown
AU  - Pia Wülfing
AU  - Zhimin Shao
AU  - Elena Rota Caremoli
AU  - Haiyan Wu
AU  - Lisa H. Lam
AU  - David Tesarowski
AU  - Melanie Smitt
AU  - Hannah Douthwaite
AU  - Stina M. Singel
AU  - Charles E. Geyer
PY  - 2019
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa1814017
UR  - https://doi.org/10.1056/nejmoa1814017
ER  -

APA

Minckwitz, G. V., Huang, C., Mano, M. S., Loibl, S., Mamounas, E. P., Untch, M., Wolmark, N., Rastogi, P., Schneeweiss, A., Redondo, A., Fischer, H. H., Jacot, W., Conlin, A. K., Arce-Salinas, C., Wapnir, I. L., Jackisch, C., DiGiovanna, M. P., Fasching, P. A., Crown, J. P., Wülfing, P., Shao, Z., Caremoli, E. R., Wu, H., Lam, L. H., Tesarowski, D., Smitt, M., Douthwaite, H., Singel, S. M., & Geyer, C. E. (2019). Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1814017

Source records

crossref · retrieved 2026-11-10T11:27:56.876Z